International Pharmaceutical Federation
Annual Report 2016

Putting people first
# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOREWORD FROM THE PRESIDENT</td>
<td>3</td>
</tr>
<tr>
<td>SNAPSHOTS 2016</td>
<td>5</td>
</tr>
<tr>
<td>ABOUT FIP</td>
<td>9</td>
</tr>
<tr>
<td>MEMBERSHIP</td>
<td>11</td>
</tr>
<tr>
<td>VIGNETTES 2016</td>
<td>13</td>
</tr>
<tr>
<td>Focus on our profession and practice</td>
<td>13</td>
</tr>
<tr>
<td>Health benefits for our communities</td>
<td>15</td>
</tr>
<tr>
<td>Education and human resources</td>
<td>17</td>
</tr>
<tr>
<td>Collaborations and partnerships</td>
<td>19</td>
</tr>
<tr>
<td>WORLD PHARMACISTS DAY</td>
<td>21</td>
</tr>
<tr>
<td>76TH WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES</td>
<td>22</td>
</tr>
<tr>
<td>AWARDS</td>
<td>23</td>
</tr>
<tr>
<td>ELECTIONS &amp; COUNCIL DECISIONS</td>
<td>25</td>
</tr>
<tr>
<td>GLOBAL CONFERENCE ON PHARMACY &amp; PHARMACEUTICAL SCIENCES EDUCATION</td>
<td>26</td>
</tr>
<tr>
<td>PUBLICATIONS</td>
<td>27</td>
</tr>
<tr>
<td>WORK IN PROGRESS</td>
<td>28</td>
</tr>
<tr>
<td>FINANCES</td>
<td>30</td>
</tr>
</tbody>
</table>
The International Pharmaceutical Federation (FIP), through its officers, staff and members, engaged in numerous activities throughout 2016. But whatever our actions, whether they were discussions with health ministers, hosting meetings or issuing guidance — to name but a few — people were at the heart of them. We made this fact loud and clear with our 2016 World Pharmacists Day theme “Caring for you”, which was taken up by our profession with pride across the globe (see p21). This fact was also reflected with our annual congress theme “Rising to the challenge. Reducing the global burden of disease” (see p22).

Attention to people — patients, pharmacists, pharmaceutical scientists, pharmaceutical educators and other health care professionals — and the health of our communities is at the core of FIP. In 21st century society, we must explore new ways to conceive health care. We want the best treatment results to be achieved for patients in coordination with the health professionals attending them. The system should follow the patient rather than the patient following the system, and that requires advancing with a holistic, transversal approach that allows close collaboration among all health professionals and at all levels of care, generating coherence and continuity, increasing efficiency and promoting knowledge. In 2016, we continued to work on important partnerships in furtherance of our goals (see p19).

“Whatever our actions, whether they were discussions with health ministers, hosting meetings or issuing guidance — to name but a few — people were at the heart of them.”

To impact on the lives of patients positively through pharmaceutical care requires the use of scientifically validated interventions developed by applying pharmaceutical sciences concepts. For instance, science is a fundamental part of the solution to global challenges such as antimicrobial resistance. This is why every three to four years, FIP hosts the Pharmaceutical Sciences World Congress (PSWC), providing a much needed forum for pharmaceutical scientists across the globe to engage in concerted efforts. I am delighted that the programme of the sixth PSWC, to be held in Stockholm, Sweden, in May 2017, recognises the importance of collaboration with clinical practitioners in maximising the desired therapeutic benefits of medicines while limiting undesired adverse events associated
FIP supports its member organisations — national professional associations — in making positive changes and preventing negative ones in their communities. In 2016, we continued to assist them, providing tools and giving advice and advocacy in convincing policymakers of our member organisations’ arguments, whether they were over medicines shortages (see p15), pharmacy services (see p14), public safety (see p5) or otherwise. In other words, we defend the interests of patients through our profession.

It remains for me to thank the officers, volunteers and staff of FIP for their dedication in 2016. Our communities, whether large or small, need to be and are connected through FIP. I have no doubt that together we will continue to transform pharmacy and, as a result, achieve the best for our communities — our people — around the world.

Carmen Peña
President
International Pharmaceutical Federation (FIP)

“Through our great efforts on education and workforce the United Nations recognised the number of pharmacists in a country as an indicator of well-being last year.”
Demonstrating broad expertise
From supporting migrant populations with improving their health to reducing the environmental impact of medicines, applying the expertise of pharmacists and pharmaceutical scientists in these endeavours was the common thread of the statements we gave at the 138th World Health Organization Executive Board meeting in Geneva, Switzerland. Statements were also given by FIP on behalf of the World Health Professions Alliance (WHPA).

Raising public health concerns
We lobbied Italian policymakers, drawing attention to the negative effect a new law being considered by the Italian Senate could have on public health. The new legislation could have led to prescription-only medicines being supplied by druggists and parapharmacies, threatening patient safety and health outcomes. FIP supported its member organisation Federfarma and Italian pharmacies, arguing that, if adopted, the new law would generate health problems through suboptimal use of medicines and additional costs for the health system. In the end, the Government withdrew its proposal of allowing parapharmacies to dispense certain prescription-only medicines.

Empowering women
Women are the non-professional caregivers closest to health care professionals and, more often than not, are the ones who go to pharmacies and assume responsibility for health in the household. We established a new working group on women and responsible use of medicines. Part of the work of the group is to gather evidence of the roles women play in contributing to good health and disease prevention. The group will also gather evidence of the roles of pharmacists as agents of women’s empowerment through supporting and promoting their education, and providing them with the information they need to ensure medicines are used responsibly. Our aim is to bring about positive change in this area.
Meeting local needs in Africa
We shared our knowledge with directors of pharmacy and medicines from ministries of health of sub-Saharan African countries at a meeting in Paris, France, thus enabling them to better tailor their development of pharmaceutical policies to meet the needs of their people. Our CEO Luc Besançon presented these policymakers with information on the evolution of pharmacy and global trends, including details of new pharmacy services that have been effectively implemented in developing countries.

Helping victims of violence
Violence, particularly against women and children, must be eliminated with the help of all stakeholders, including pharmacists, we told health ministers at the 69th World Health Assembly in Geneva, Switzerland. We explained how pharmacies, as conveniently accessible sources of advice, offer a place where victims can be supported to take the first steps in reporting violence, using examples of actions of community pharmacist colleagues in Germany and Spain to raise awareness of this serious issue. This was among 10 areas on which FIP made statements to the assembly.

Looking out for children
To address gaps in children’s medicines, the World Health Organization (WHO) and FIP released new guidelines for health care professionals prescribing or supplying medicines for children when no authorised product exists. This means that health professionals now have evidence-based or best practice advice about alternatives to compounding of medicines for children so that the risk of providing child-specific preparations without informed knowledge is reduced. We are proud to be recognised as the experts in medicines, as evidenced by these joint FIP-WHO technical guidelines.
Preventing for disasters
Considering that the world is experiencing an increasing number of natural disasters, such as floods, heat waves and earthquakes, our Board of Pharmaceutical Practice set up a working group to address the questions that should be considered at national, regional and individual pharmacy levels to assist pharmacists in providing safe and effective care. The first global guidelines that support people's continued access to medicines and pharmacy expertise during disasters — natural and man-made — were released in July following extensive consultation. The document, "Responding to disasters: Guidelines for pharmacy", describes actions for different parties under each of the four phases of an emergency: prevention/risk mitigation, preparation/readiness, response and recovery. We were pleased to see New Zealand’s Ministry of Health endorsing these guidelines later in the year, disseminating them to all hospital boards and community pharmacies with a recommendation to use them as a planning resource. Even when the unforeseen happens and emergency strikes, pharmacists are the forefront of care.

Protecting people through vaccine coverage
Over 193,000 pharmacies worldwide can potentially offer access to vaccinations to at least 940 million people, new research commissioned by FIP revealed. Our global report "An overview of current pharmacy impact on immunisation", said that, based on a global population of 7.4 billion, this represents at least one in eight people. This new role, recognised by the WHO, is to be considered in addition to pharmacies' active involvement in the vaccine supply chain and in providing advocacy to patients on the importance of immunisation. The report encourages the recognition of pharmacists as immunisers and we look forward to a day when pharmacists around the world can act to their full potential, adding to the immunisation services offered by other healthcare professionals, especially to hard-to-reach and high-risk populations.

Fighting fake medicines
We led an international campaign to make people aware of the dangers of fake medicines, in collaboration with global organisations representing doctors, nurses, dentists and physical therapists. The campaign's interactive video "Counter the Counterfeits", which also called on policymakers and health professionals to take action, was viewed by at least 170,000 people around the world. The campaign was covered in the press, by stakeholders (e.g., Fight the Fakes, National Association of Boards of Pharmacy, the Alliance for Safe Online Pharmacies) and on social media, with the FIP Facebook reach alone amounting to almost 850,000 views. The Icelandic Medicines Agency used the video, as did pharmacists organising meetings in China Taiwan, Costa Rica, Ghana, Nigeria and Zambia. The video was also shown in Austria on a website jointly run by the country's Ministry of Health, police and Chamber of Pharmacy.
Influencing United Nations action on health workforce

Ministers were told how our profession has made workforce issues a high priority and is committed to transforming the pharmacy workforce so that the United Nations Sustainable Development Goals (SDGs) can be achieved. Speaking at the High-Level Ministerial Meeting on Health Employment and Economic Growth in Geneva, Switzerland, our CEO Luc Besançon highlighted the many ways in which our profession has been putting (and will continue to put) the conclusions of the UN High-Level Commission on Health Employment and Economic Growth into action. Appreciation of our work was evident when our President Carmen Peña was invited to moderate the meeting’s roundtable on accelerating investments in scaling up transformative education and skills. Moreover, mention increasing health care costs due to lengthier hospital stays. In 2016, our AMR work also included taking part in a working group of representatives from all health care professional associations in Norway in September, providing a global perspective, including on pharmacists, to feed their work for an interprofessional action plan on AMR. Our input into the WHO AMR Global Action Plan continues.

Combatting antimicrobial resistance

The latest development in our long-term work on antimicrobial resistance (AMR) was the official and specific involvement of pharmacists by the World Health Organization in World Antibiotic Awareness Week. We worked with the WHO on developing and spreading the campaign, in particular, five simple things that pharmacists can do to help prevent AMR. AMR threatens our ability to treat common infectious diseases and results in prolonged illness, disability and death, not to mention increasing health care costs due to lengthier hospital stays. In 2016, our AMR work also included taking part in a working group of representatives from all health care professional associations in Norway in September, providing a global perspective, including on pharmacists, to feed their work for an interprofessional action plan on AMR. Our input into the WHO AMR Global Action Plan continues.

Supporting national pharmacy planning

The ability of pharmacists to provide care for their communities commonly depends on the terms of national pharmacy contracts. FIP often helps its member organisations to prepare for these essential negotiations. For example, in October, our CEO Luc Besançon visited the Fédération des Syndicats Pharmaceutiques de France headquarters in Paris, where he shared FIP’s knowledge of the evolution of pharmacy services at an international level, presenting different strategies that have worked in other countries, in order to inform the syndicate’s preparation for discussions of a new five-year pharmacy contract.

OCTOBER

NOVEMBER

DECEMBER
ABOUT FIP*

* As at May 2017

WHO WE ARE

The International Pharmaceutical Federation (FIP) is the global federation of national associations of pharmacists and pharmaceutical scientists. With 139 member organisations we represent more than three million experts in medicines.

FIP is a non-governmental organisation that has been in official relations with the World Health Organization since 1948. Through our partnerships and our extensive global pharmacy and pharmaceutical sciences network, we work to support the development of the pharmacy profession, through practice and emerging scientific innovations, in order to meet the world’s health care needs.

We represent more than three million experts in medicines.

WHAT WE DO — VISION AND MISSION

Our strategy ("2020 Vision") is to ensure that FIP is an integral participant in global health care decisions and actions. As such, the vision that FIP holds is that wherever and whenever decision-makers discuss any aspects of medicines on a global level, FIP is at the table.

FIP is enabled to succeed in this vision through the recognition and respect it gains in the fulfilment of its mission, which is to improve global health by advancing pharmaceutical education, sciences and practice thus encouraging, promoting and enabling better discovery, development, access to and responsible use of appropriate, cost-effective, quality medicines worldwide.

Molecules only become medicines when pharmaceutical expertise is added. Pharmacists, through ensuring their responsible use, optimise the effects of these medicines.

Examples of what we do and the impact we have can be found in the pages of this annual report.

HOW WE WORK — STRUCTURE

FIP activities can be divided into three main areas — science, practice and education — although there is increasing collaboration between these areas.

One of our objectives is to advance the pharmaceutical sciences and this is primarily done through the work of nine special interest groups (SIGs) led by the Board of Pharmaceutical Sciences. There are SIGs for:

- Analytical sciences and pharmaceutical quality
- Biotechnology
- Drug design and discovery
- Formulation design and pharmaceutical technology
- Natural products
- Pharmacokinetics, pharmacodynamics and systems pharmacology
- Pharmacy practice research
- Regulatory sciences
- Translational research and individualised medicines

Another of our objectives is to advance pharmacy practice in all settings, and this is done through the projects and initiatives of eight pharmacy practice sections. There are sections for:

- Academic pharmacy
- Clinical biology
- Community pharmacy
- Health and medicines information
- Hospital pharmacy
- Industrial pharmacy
- Military and emergency pharmacy
- Social and administrative pharmacy

The reform of pharmacy and pharmaceutical sciences education in the context of pharmaceutical workforce development is a third objective and this is the purpose of FIP Education (FIPEd).
FIP directs particular effort to young pharmacists and the preparation of congresses, through its Young Pharmacists Group and Congress Programme Committee, respectively. In addition, among the boards, sections, SIGs and committees are ad hoc working and focus groups.

FIP is governed by a Council and Bureau (board). The Council is FIP’s highest administrative organ and all member organisations have voting rights. (Our observer organisations participate in the Council but cannot vote.) The Council also includes representatives from the FIP sections and the Bureau. The Bureau consists of 15 elected officers (plus the FIP chief executive officer, ex officio) as follows.

- **President**
  Dr Carmen Peña (Spain)

- **Chief executive officer**
  Mr Luc Besançon (Netherlands)

- **Scientific secretary**
  Prof. Giovanni Pauletti (USA)

- **Professional secretary**
  Ms Ema Paulino (Portugal)

- **Immediate past president**
  Dr Michel Buchmann (Switzerland)

- **Chair of the Board of Pharmaceutical Sciences**
  Prof. Tatsuro Irimura (Japan)

- **Chair of the Board of Pharmaceutical Practice**
  Mr Dominique Jordan (Switzerland)

**Nine vice presidents (one election pending)**

- Mr Andrew L. Gray (South Africa)
- Dr Linda Hakes (UK)
- Prof. Ross McKinnon (Australia)
- Mr Tom Menighan (USA)
- Dr Eduardo Savio (Uruguay)
- Prof. Philip J. Schneider (USA)
- Ms Eeva Teräsalmi (Finland)
- Mr Nobuo Yamamoto (Japan)

FIP’s day-to-day activities are managed by an executive committee and a team of staff at our headquarters in the Netherlands.

The individual annual reports of the SIGs and sections are available at fip.org.
**FIP Membership**

Through our membership, FIP has presence in 148 countries and territories. This covers over 7.2 billion people.

- 139 Member organisations
- 152 Academic institutional members
- 21 Observer organisations
- 4,100 Individual members
NEW OBSERVER ORGANISATIONS
At its meeting in August 2016, the FIP Council admitted the FIP Foundation for Education and Research as a new observer organisation.

A full list of FIP observer organisations can be found at http://bit.ly/1CsA0NF.

NEW ACADEMIC INSTITUTIONAL MEMBERS
FIP welcomed the following schools of pharmacy as academic institutional members in 2016:

- European University Cyprus (Cyprus)
- Quest International University Perak (Malaysia)
- Ramon Llul University (Spain)
- Universidad Miguel Hernández de Elche (Spain)
- University of Ljubljana (Slovenia)
- University of Putthisastra (Cambodia)

A full list of FIP academic institutional members can be found at http://bit.ly/2q1tC2I.

Dr Richard Townley, CEO, Pharmaceutical Society of New Zealand, Inc.

“The Pharmaceutical Society of New Zealand joined FIP to further its role of leadership of the profession in New Zealand. Being a member of FIP, the recognised international leading organisation for our profession, brings highly respected international pharmacy networks and spheres of influence, a policy-setting environment for professional guidance and future focus, and the platform to share innovation. New Zealand has already benefited from its membership and involvement with FIP Ed.”

Dr Allan Mathews, dean, Quest International University Perak, Malaysia

“As Quest International University Perak is a relatively young university it was important for us to join FIP’s academic institutional membership to make use of its network and share knowledge and experience with other universities all over the world. At QIUP we believe that planting the seeds of curiosity in students from the beginning of their education will inspire them to make ‘knowledge-seeking’ their quest in life. The university provides holistic education which prepares the graduates for the real world. Therefore, we make it our mission to offer our students cutting-edge educational programmes that impact the local and global knowledge-economy, and promote research and innovation in frontier disciplinary and interdisciplinary areas. We envisage that our membership will help us along the way.”

Dr Raymond Muganga, chair, Rwanda National Pharmacy Council

“Joining FIP is an opportunity to network and collaborate with sister organisations with similar roles in Africa and elsewhere in the world towards development of pharmacy profession globally and particularly in Rwanda.”

Mr John Ware, chair, FIP Foundation for Education and Research

“To achieve its mission, FIP is assisted by the FIP Foundation for Education and Research. The board and the chair are appointed by the FIP Bureau. Being officially recognised as an observer organisation will allow for a comprehensive knowledge of directions, objectives and projects being targeted by FIP. After all, FIP is the reason for the foundation’s existence in its supportive role.”

PUTTING PEOPLE FIRST
FOCUS ON OUR PROFESSION AND PRACTICE

PROMOTING PHARMACY IN THE BALTIC STATES

Pharmacists are the solution to many health challenges, FIP President Carmen Peña told Lithuanian Minister of Health Juras Požela at their meeting in Vilnius in April 2016. Among the topics of discussion was pharmacists’ value in supporting medication adherence. During her visit to our member the Lithuanian Pharmaceutical Association, Dr Peña also took the opportunity to tell the public, through an interview with the Baltic News Service, that pharmacists are first and foremost health care professionals, rather than business people.

Prof. Eduardas Tarasevicius, President, Lithuanian Pharmaceutical Association

“In April, FIP president Dr Carmen Peña also met with the Deputy Speaker of the Seimas (Parliament) of the Republic of Lithuania Mrs Irena Degutiene and informed her about FIP’s mission to renew pharmacy and to ensure that the pharmaceutical profession remains significant and able to respond efficiently to the current needs of our society. In addition, Dr Peña presented her views on ‘A new pharmacy for a new society’ at the 19th international conference ‘BalPharm Forum’ to pharmacists from three Baltic countries: Lithuania, Latvia and Estonia. The audience was inspired by this thoughtful presentation, which was focused on three main areas: patients, services and sustainability.”

GIVING PROMINENCE TO INNOVATIVE WORK

An overview of 103 new activities run by FIP member organisations, ranging from professional services to public health initiatives, advocacy work and pharmacy education reforms, was presented in a new FIP report in May 2016. “FIP member organisation programmes and activities”, brings together a wealth of data, strategies and outcomes in an easy-to-navigate format. It is intended to offer a source of inspiration and drive innovation and strategic planning, exclusively for FIP member organisations. FIP also held a webinar for its member organisations to present the key elements of this report. To give further prominence to innovative models, FIP launched two new member organisation awards in 2016 (see p23).
FACILITATING STRATEGIES FOR PRACTICE DEVELOPMENT

Many pharmacy services are being offered and paid for based on evidence from practice. To this end, FIP established a new Special Interest Group on Pharmacy Practice Research in July 2016. One objective is to allow exchange of information on practice research in order to produce high quality evidence at an international level and, ultimately, to increase pharmacy contributions to global health. “The scope of pharmacy practice research has expanded over the past 50 years to encompass the clinical, behavioural, economic and humanistic implications of the practice of pharmacy, health care systems, medicines use and patient care. The development of new services is also, more and more, being influenced by practice research,” said Prof. Charlie Benrimoj, the group’s first chair and head of the Graduate School of Health at University of Technology, Sydney, Australia.

Dr Charlotte Rossing, head of research and development, Pharmakon, Denmark

“Contemporary pharmacy practice has to be based on robust evidence. The new Special Interest Group on Pharmacy Practice Research within FIP is the worldwide platform for the development of science-based practice.”

LEADING COLLABORATIVE VISION ON SERVICES

The advocacy work performed by FIP in 2016 included attendance at the annual meeting of the European Healthcare Distribution Association (GIRP) in the Netherlands in June 2016. Under the theme “Healthcare distribution — A vision for the future”, our CEO Luc Besançon spoke to pharmaceutical wholesalers about the importance of innovation of pharmacy services driven by national associations of pharmacists.

Ms Monika Derecque-Pois, CEO, European Healthcare Distribution Association

“With a commitment to putting patients first, health care distributors and pharmacies guarantee a high quality and safe distribution infrastructure for medicines. The professional role of the pharmacist is paramount to health care delivery, and health care distributors work with pharmacies to support them in the development and delivery of high quality effective health care services. In this respect, we highly value the collaboration with FIP and welcomed the contribution of Mr Luc Besançon to our annual meeting and conference in 2016 where we acknowledged the pharmacist’s role in the provision of patient services.”

ENABLINGS RESEARCH TO IMPROVE HOSPITAL PRACTICE

FIP’s Hospital Pharmacy Section established a process for grants in 2016 to help ensure that research around the uptake and implementation of the Basel Statements in order to improve hospital pharmacy practice and patient care continues. Two projects are currently under way in Brazil and the USA.

Dr Stephen Eckel, PACE associate director of pharmacy, UNC Hospitals, USA

“I am very happy that the HPS has placed a priority on research, especially focusing on research around the Basel Statements. The HPS Research Committee has overseen this new granting scheme, and it is wonderful to be part of this collaboration.”
HEALTH BENEFITS FOR
OUR COMMUNITIES

SOLVING SHORTAGES AND IMPROVING ACCESS

An area that remains a challenge for too many people is access to medicines, and this is exacerbated by the huge issue of shortages. For medicines to offer benefit, they first need to be available. We continued to engage policymakers to come up with and implement new solutions to supply problems in 2016 and our years of investing in this work since the landmark FIP International Summit on Medicines Shortages of 2013 began to see results. We were pleased, for example, to see six of the recommendations from our summit reflected in the World Health Organization’s resolution, in May, to address the global shortage of medicines and vaccines. We kept up our efforts during the year, for instance, offering support to our member organisation in Venezuela, where there are devastating shortages, and bringing the plight of the Venezuelan people to the fore at the World Health Assembly, highlighting that 75% of medicines were unavailable. That international collaboration is required in order to manage large-scale shortages was acknowledged in a commentary by WHO staff in September 2016, which also referenced the FIP summit report. We also contributed to the work of the United Nations High-level Panel on Access to Medicines, promoting pharmaceutical sciences and research, development, innovation and increased access to medicines, vaccines, diagnostics and related health technologies.

Dr Gilles Forte, coordinator, policy, governance and knowledge management, Essential Medicines and Health Products Department (EMP), World Health Organization

“FIP has been instrumental for bringing the issue of shortages of medicines and vaccines high on the international health agenda. WHO and FIP are working hand in hand to address global shortages of medicines and vaccines and to promote the role of the pharmacist in improving efficiency and integrity of the supply chain and mitigating stock outs in countries.”

FOCUSING ON SAFETY

Our work on medicines safety also continued in 2016. FIP was a guest at World Health Organization headquarters in Geneva, Switzerland, in April, contributing to the WHO Global Patient Safety Challenge on Medication Safety. The meeting identified the next steps needed to strengthen the medicines use process and to reduce medication errors, for example, by involving national health care professional associations in the implementation process, via interprofessional collaborative practice and improving communication. Safety around herbal medicines is also a concern and, in July, Prof. Michiho Ito, chair of FIP’s Special Interest Group on Natural Products, lent her expertise as a pharmacist to the WHO’s development of guidelines on interactions of herbal medicines with other medicines.

Prof. Michiho Ito, president, chair, FIP Special Interest Group on Natural Products

“The use of herbal medicines with modern medicines, such as traditional herbal formulas with anticancer medicines, is increasing because some herbal medicines have been shown to increase quality of life of patients, particularly in cases where the modern medicine has unwanted side effects. Development of this WHO guideline is important to promote safe use of herbal medicines with conventional medicines. It was good for FIP to show its leadership in developing guidelines for modernised use of herbal medicines through our inclusion in the editorial committee.”
CARING FOR PATIENTS WITH RESPIRATORY DISEASES

Chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease, kill more than four million people every year and affect hundreds of millions more. These diseases erode health and well-being and have a negative impact on families and societies, constituting a serious public health problem in all countries. To better equip pharmacists to care for patients with chronic respiratory diseases FIP’s Community Pharmacy Section offered a series of free webinars in 2016, focusing on helping patients to make the most of their therapies, and building services for these patients. Some 3,452 pharmacists from 86 countries registered to attend.

TACKLING OPIOID ABUSE

The worldwide problem of opioid abuse was a hot topic tackled by FIP scientists in 2016. At a session organised by our Special Interest Group on Drug Design and Discovery at the 76th World Congress of Pharmacy and Pharmaceutical Sciences, participants learnt about opioid-induced hyperalgesia, opioid withdrawal, mechanisms of opioid tolerance, how to address these based on the information that patients and science provide, and opioid side effects. For many years, scientists have been searching for an opioid-receptor agonist without the undesirable side effects displayed by morphine-like drugs, and participants heard from award-winning scientist Prof. Hiroshi Nagase, of the University of Tsukuba, Japan, about research on a drug with the absence of such side effects. Through research like this, pharmaceutical scientists are putting people first.
EDUCATION AND HUMAN RESOURCES

ADVANCING WORKFORCE COMPETENCIES

A collection of achievements, ranging from the credentialing of advanced pharmacy practice in Australia and the set-up of a new pharmacy curriculum in Chile to the adoption of a competency framework in Croatia and the development of a model to evaluate health care professionals in Jordan, was presented in a new FIP Education (FIPEd) report, “Transforming our workforce”, published in September 2016. The report not only showcased how universities, professional organisations and authorities around the world have been enabled to take steps towards ensuring that pharmacists are capable and competent thanks to resources produced by FIPEd over the past decade, but also demonstrated how the pharmacy profession is advancing in different countries.

Prof. Ian Bates, FIPEd education development team director

“All counties are facing similar demographic and economic challenges in providing universal and high quality health and pharmaceutical care; workforce is central to many of these national challenges. This report demonstrates potential workforce solutions, national policy tools, practitioner-based solutions and leadership directions that are transferable to all countries; it is a valuable support document for the recently launched workforce development goals that will push forward our pharmaceutical workforce.”

TALKING HUMAN RESOURCES

We invited Dr Charles Boguifo, the president of FIP’s membership organisation in Côte d’Ivoire, Conseil National de l’Ordre des Pharmaciens de Côte d’Ivoire, to represent FIP at the World Health Organization’s intersectoral francophone consultation on health employment and economic growth in Africa in June 2016, which engaged ministries of health, education, labour/employment, higher education and finance, as well as United Nations agencies and global health initiatives. Issues on the agenda included financing for education and health employment and the international mobility of health workers. He was the only pharmacist at the discussion.

Dr Charles Boguifo, president, Conseil National de l’Ordre des Pharmaciens de Côte d’Ivoire

“It is unthinkable to talk about human resources for health without the involvement of health care professionals from the private sector, especially as, in many countries, they provide more than 70% of health care. Similarly, it would be unthinkable to talk about the health care sector without considering the pharmaceutical sector, as it represents more than 80% of the supply of care. Since pharmacists are now considered in the indicators for the achievement of the sustainable development goals and as they are one of the main gateways to health care for patients under treatment or for triage/referral, it was therefore crucial that FIP and pharmacists were represented in this meeting.”
PROVIDING PROFESSIONAL DEVELOPMENT FOR EDUCATORS

Experiential education and the various methods by which it is delivered around the world and where it needs to be enhanced was the topic of a webinar hosted by FIP’s Academic Pharmacy Section in May 2016. Experiential education places an emphasis on people and putting students, faculty and patients first and foremost by training students to provide high quality patient-centred care. In October 2016, the section hosted a second webinar on leadership development. In fact, a number of FIP sections stepped up their webinar activities in 2016, with 11 webinars being offered.

Prof. Toyin Tofade, dean, Howard University College of Pharmacy, Washington DC, USA, and secretary, FIP Academic Pharmacy Section

“The webinars provide a way for our members to participate in and engage with other colleagues from around the world from the comfort of an office or computer. Many members are not privileged to attend the annual congress and therefore the section is happy to provide this opportunity to all its members. Members have the opportunity to invite their colleagues. The leadership webinar was also very helpful for faculty to apply leadership skills in their teaching.”

SUPPORTING LEARNING OPPORTUNITIES

Each year FIP’s Health and Medicines Information Section (HAMIS) offers a grant to support a pharmacy student, pharmacist or pharmaceutical scientist to attend the World Congress of Pharmacy and Pharmaceutical Sciences. Fifteen applications were received for 2016. The successful applicant was Ms Chinara Razzakova, a doctoral student from the Institute of Fundamental Medicine and Biology, Kazan Federal University in the Republic of Tatarstan, the Russian Federation.

Ms Chinara Razzakova, HAMIS grant beneficiary, Russian Federation

“I had the opportunity to meet highly respected scientists and clinical pharmacists, which was very helpful to me to adopt their experience. I was impressed with the quality of the reports, which were [full of] new and evidence-based information…. Knowing what our colleagues from other countries do gave me ideas for new projects which can be implemented in the Russian Federation. I was deeply impressed by the work of researchers, which gave me great motivation to work further and harder.”

EMPOWERING OUR PEOPLE

In 2016, FIP’s Young Pharmacists Group launched a mentorship programme. Its aim is to provide support for young pharmacists developing their careers in the diverse world of pharmacy. The programme facilitates a bond between established and young professionals so that knowledge, experience and guidance can be shared with an international approach to development. The programme is now being further developed by the YPG, FIP staff and the International Pharmaceutical Students’ Federation.

Dr Oscar Ekpenyong Jr, graduate research assistant, College of Pharmacy and Health Sciences, Texas Southern University, USA

“Approaching the finish line of my doctoral education and torn between career choices, I had a strong desire to address several of my interests and maximise my professional potentials. Being a mentee helped me develop vital scientific, professional and leadership skills. Through the mentorship programme, I was able to expand my knowledge, build professional networks and gain valuable counsel from an experienced mentor. The programme satisfied my professional development needs and career objectives. I sincerely hope that young pharmacists/pharmaceutical scientists will avail themselves of this opportunity to grow professionally and personally, and now I look forward to being a mentor to other people.”
COLLABORATIONS AND PARTNERSHIPS

ACTING IN THE PUBLIC INTEREST

Health professional regulation faces many challenges in a world of political, social, economic and technological change. Widespread reform of health professional regulation reflects policy initiatives by many governments to ensure sustainable, efficient and effective health service delivery to our communities. As a continued partner in the World Health Professions Alliance, FIP contributed to the 4th World Health Professions Regulation Conference in May 2016, where discussions focused on health professional regulation and trade agreements — protecting the public versus facilitating commerce — balancing regulation of individual health professionals and health services, and the WHO Global Strategy on Human Resources for Health and sustainable development goals.

FIP professional secretary Ema Paulino gave the opening remarks at the conference in Geneva, Switzerland, where FIP-invited speakers from the National Association of Boards of Pharmacy (USA) and the French National Chamber of Pharmacists gave presentations on regulation versus technology and EU regulation of health care, respectively.

Mr Enzo Bondioni, executive director, World Dental Federation

“The World Dental Federation (FDI) collaborates closely with the world’s physicians, nurses, pharmacists and physical therapists through its membership of the World Health Professions Alliance. An example of such collaboration was FDI’s partnership with FIP, which launched an interactive video entitled “Counter the counterfeits”. This provided important information to the public, health care professionals and policy makers on the dangers of fake medicines [See p7].”

OPTIMISING HEALTH RESOURCES

Possible strategies to optimise the scopes of practice of health workers in Organisation for Economic Co-operation and Development (OECD) countries were shared by our CEO Luc Besançon when he was invited to take part in an OECD Health Division meeting held in Paris, France, in June. The aim was to foster meaningful discussions on the efficient use of health human resources, key policy levers and organisational factors, with focus primarily on nurses and pharmacists, through advanced roles and functions within health care systems. During the event, FIP also presented government officials with evidence of the diverse advanced roles that pharmacists play, telling them that further extension of roles could help deliver huge health care cost savings.

The summary of the conference is available online.

Mr Gaetan Lafortune, senior economist, OECD Health Division

“The OECD welcomed FIP participation at its workshop to discuss innovative ways to promote a more efficient use of health human resources. FIP contribution to this one-day workshop, which gathered representatives from Ministries of Health from OECD countries, professional associations and leading academics, clearly highlighted that the main criteria that should guide the development of new roles for pharmacists and other health professionals should be, first and foremost, to promote more people-centred care and greater teamwork.”
SUPPORTING LEADERSHIP

Following a suggestion by FIP to the regional pharmaceutical forums to identify priorities for action through “regional project labs” — interactive workshops based on a design-thinking approach — the Western Pacific Pharmaceutical Forum (WPPF) organised its first Regional Leaders’ Summit in Manila, Philippines, in September 2016. The summit was attended by pharmacy leaders from 12 different countries or territories from across the region. The primary objective was to identify significant pharmacy practice-related issues in countries of the region and to develop a strategy and work-plan to address the major common issues. FIP’s manager for profession development, Gonçalo Sousa Pinto, supported the summit, presenting resources of relevance for the region, and moderating two of the workshops. Delegates determined that the WPPF should provide support to national pharmacy associations to develop professional development frameworks and assist in the formulation of mutual recognition agreements among countries in the region with regard to harmonised descriptors of competencies. The WPPF will further develop the work-plan.

Mr John Jackson, president, Western Pacific Pharmaceutical Forum

“The support of FIP enabled us to host an exceptionally beneficial regional summit of pharmacy leaders. The commitment and engagement of the participants was amazing. The outcome was a work plan to address the major regional issue of competency and professional development.”

COOPERATING IN THE FIELD OF SCIENCE

FIP’s Board of Pharmaceutical Sciences worked with various national organisations in 2016 to underline the relevance of pharmaceutical sciences for the development of safe and effective medicines, such as through an FIP science-practice forum held at the 2016 annual meeting of the Pharmaceutical Society of Japan in Yokohama in March. The board also co-sponsored events including the 2nd International Symposium on Drug Product Quality Equivalence and Regulations in the Philippines, and a Hands-on-Dissolution Workshop in Romania. At the 2nd International Workshop on Harmonization of Bridging Studies among the Asia-Pacific Region, held in China Taiwan, in June, pharmaceutical scientists and representatives of national regulatory authorities discussed more efficient strategies for enabling market approval of clinically relevant new medicines already approved in different regions of the world without jeopardising country-specific safety standards.

Prof. Takuya Kumamoto, member of the International Affairs Committee, Pharmaceutical Society of Japan

“The Pharmaceutical Society of Japan has hosted an ‘FIP Forum’ at its annual meetings since 2012 to introduce the activities of FIP. In 2016, FIP’s scientific secretary Dr Giovanni Pauletti shared the latest activities of the FIP Board of Pharmaceutical Sciences, and three Japanese scientists, active in the field of pharmacokinetics/pharmacodynamics and personalised medicine, presented their research activities. About 50 people joined the meeting, which was a good opportunity to integrate pharmaceutical science with pharmacy practice to improve pharmaceutical care of patients.”

PROTECTING HEALTH CARE WORKERS

Our president Carmen Peña met in December with Yves Daccord, director-general of the International Committee of the Red Cross, in Geneva, Switzerland, to sign a memorandum of understanding in which both parties agree to cooperate on projects beyond the Health Care in Danger (HCiD) initiative, which FIP has supported for some years. The HCiD campaign highlights that any violence against health care professionals, including pharmacists, is unacceptable. The memorandum is an important step in nurturing the relationship between FIP and the Red Cross.

Mr Yves Daccord, director-general, International Committee of the Red Cross

“We can’t make access to health care and its delivery safer by working in silos, bringing pharmacists together with doctors, nurses and other health professionals is key. This memorandum of understanding helps us make a stronger impact and take our collaboration with FIP even further.”
World Pharmacists Day is used by FIP’s members and our profession around the globe to highlight the impact and added value of the pharmacy profession and its role in improving health to authorities, other professions and the media, as well as to the general public. Its purpose is to encourage promotion and advocacy for the role of the pharmacist in improving health in every corner of the world.

“Pharmacists: Caring for you” was the theme for World Pharmacists Day 2016, designated by the FIP Bureau. This reflected pharmacists’ emotional connection to patients and the important role they have in providing care to the public. FIP produced free campaign materials which, for the first time, were available in the six official United Nations languages and featured real pharmacists.

We are proud that World Pharmacists Day has become so popular. In its sixth year in 2016, it was marked by pharmacists all over the globe, who celebrated with activities from rallies and free-of-charge health screening to seminars and counselling competitions.

1) World Pharmacists Day offered Mohamed Mabrouk the opportunity to be interviewed on Libyan radio
2) In Belarus, colleagues organised free counselling sessions to inform the public about disease prevention and nutrition
3) Pharmacists in Yogyakarta, Indonesia, informed people on the street about safe use, storage and disposal of medicines
Perhaps there can be no greater illustration of putting people first than the theme of FIP’s 76th World Congress of Pharmacy and Pharmaceutical Sciences: “Rising to the challenge: Reducing the global burden of disease”. The congress programme also included focus on Zika virus and infectious diseases, reflecting provision of information to pharmacists on topics of immediate concern to our populations.

The congress was held in Buenos Aires, Argentina, from 28 August to 1 September 2016, and was co-hosted with the Argentinian Pharmaceutical Confederation (Confederación Farmacéutica Argentina, COFA).

Participants: 2,235 (from 93 countries).
Speakers: 235
Abstracts presented: 593
Countries accrediting CPD/CE: 12
(Accreditors: Argentinian Pharmaceutical Confederation, Austrian Chamber of Pharmacists, Accreditation Council for Pharmacy Education [USA], Council on Pharmacists Credentials [Japan], Federal Union of German Associations of Pharmacists, FPH [Switzerland], Norwegian Association of Pharmacists, Portuguese Pharmaceutical Society, Pharmaceutical Chamber of Macedonia, Royal Dutch Pharmacists Association, Royal Pharmaceutical Society [UK], and Swedish Pharmacists Association)

Participants listed the following as being among the top benefits of attending the congress:

• “Getting the global view on pharmacy and pharmaceutical sciences”
• “Advancing pharmacy in the right direction”
• “Networking opportunities, including meeting global leaders”
• “Practical information to use in daily practice”
• “Research sharing”
• “Being inspired”

Mr Raul Mascaro, immediate past president, Confederación Farmacéutica Argentina
“The experience was excellent. It was a great opportunity to demonstrate the potential of the joint work of the Argentinian Pharmacists Confederation and its parent organisation FIP. It also allowed us to see the synergy that we have in the entity, as a working team, to achieve objectives. Above all, we were able to focus on Argentinian and Latin American pharmacy, allowing our pharmacists to present our country as a world reference for the profession, and to evolve with its knowledge as well as that of colleagues from different countries who enriched us with their experiences.”

Mr Ioan Antofe, president, National Hospital Pharmacists Association of Romania
“The experience at the congress in Buenos Aires was encouraging for the development of our association. I met colleagues from other countries with other expertise in hospital pharmacy and made new friends. Also, we learnt new things through the works presented at the congress.”

Prof. María Sol Erlij, professor at Maimónides University, Buenos Aires, Argentina
“Thank you very much for this unforgettable experience. I am from Argentina and it was a pleasure to attend this international congress for the first time. FIP 2016 was excellent.”
TWO NEW AWARDS FOR FIP MEMBER ORGANISATIONS

In 2016, FIP launched two new awards to recognise innovation in pharmacy and, by giving prominence to such work, to stimulate best practices. The award categories are Best Pharmacy Practice Improvement Programme and Best Health Promotion Campaign.

The first Best Pharmacy Practice Improvement Programme Award went to the Pharmaceutical Society of Australia for developing the concept of pharmacies as health destinations in the community and of pharmacists as providers of total health solutions. This programme aims to improve business and financial planning, people and processes, marketing, layout and infrastructure, while supporting pharmacists in building, through their expertise, new professional services responding to local needs. Participating pharmacies are visited by a coach, who provides practical advice and resources tailored to needs, and are enabled to provide a stronger focus on self care and delivery of evidence-based professional services. The programme has led to more clinical interventions and increased patient loyalty as well as average net profit increases of AUD 79,000 (EUR 52,000) per pharmacy in nine months.

Portugal’s pharmaceutical society (Ordem dos Farmacêuticos de Portugal) received the first Best Health Promotion Campaign Award for its “Medicines use — We are all responsible” campaign. Easy-to-grasp messages and materials, including a dedicated website, Facebook page and video, were created and wide dissemination through national and social media resulted in a large number of people being reached. For example, there were over 28 million television viewers and 884,000 website hits. Portuguese pharmacies actively promoted the campaign. Partnership with the Healthy Generation Project, which educates around 13,000 primary school students a year on healthy lifestyles and preventable diseases, ensured reach to a young audience. The campaign has been endorsed by Portugal’s National Authority of Medicines and Health Products as well as authorities and professional associations from Portuguese-speaking countries.

Mr Joe Demarte, president, Pharmaceutical Society of Australia

“We are proud that this work has been celebrated at an international level. It shows that, as in many countries around the world, there are many opportunities for community pharmacies to play an enhanced role in patient care despite an increasingly uncertain financial future.”

Professor Ana Paula Martins, president, Ordem dos Farmacêuticos de Portugal

“The positive impact of this campaign has been identified in population awareness and change. The campaign sets a first step in promoting best practices and habits in the responsible use of medicines among the population. Recognition of this work by FIP among so many campaigns around the world is an honour.”
OTHER AWARDS

André Bédat Award
Dr Ana I. Martinez (USA)

Joseph A. Oddis Award for Exceptional Service to FIP
Dr Dieter Steinbach (Germany)

Lifetime Achievement in the Pharmacy Practice Award
Prof. David K. Raynor (UK)

Distinguished Science Award
Prof. Shinji Yamashita (Japan)

SEVEN FELLOWSHIPS

Prof. Ralph Altiere (USA)
Prof. Michael Anisfeld (USA)
Prof. Parisa Aslani (Australia)
Mr Thony Bjork (Sweden)
Prof. Timothy Chen (Australia)
Mrs Manjiri Gharat (India)
Prof. Michiho Ito (Japan)
Ms Lindsay McClure (United Kingdom)

New FIP Fellows: (left to right) Ralph Altiere, Michael Anisfeld, Parisa Aslani, Timothy Chen, Manjiri Gharat, [FIP President Carmen Peña], Michiho Ito, Thony Björk and Lindsay McClure
ELECTIONS AND COUNCIL DECISIONS

The FIP Council, through which all member organisations have voting rights, meets once a year. At the Council meeting in August 2016, elections were held and a number of decisions were made.

Elections
Prof. Tatsuro Irimura (Japan), project professor at Jutendo University School of Medicine, was elected as the new chair of the Board of Pharmaceutical Sciences.

The following people were elected as vice presidents on the FIP Bureau (board):

**Dr Linda Hakes (UK),**
Chair, UK Academy of Pharmaceutical Sciences

**Prof. Ross McKinnon (Australia),**
Director, Flinders Centre for Innovation in Cancer

**Mr Tom Menighan (USA),**
CEO, American Pharmacists Association

**Ms Eeva Teräsalmi (Finland),**
Community pharmacist and pharmacy owner

Decisions
The FIP Council adopted a Statement on Environmentally sustainable pharmacy practices: Green pharmacy.

New FIP statutes were adopted. In brief, these modernise the governance of the federation and identify that it shall be guided by the following core values, all being equally important (Article 2.4):

- **Caring.** A focus on the individual, the family and the community;
- **Commitment.** To the development of the pharmaceutical sciences, the pharmaceutical professions and to the continued reform and improvement of pharmaceutical education;
- **Collaboration.** With all the healthcare parties involved so as to effect positive change;
- **Excellence.** Promoting and supporting best practices;
- **Integrity and transparency.** In every action that is carried out towards FIP members, partners, and other stakeholders;
- **Responsibility.** Toward both society and FIP members;
- **Spirit of inquiry.** Welcoming and showing respect for different points of view

The new statutes also formally recognise FIP Education (FIPEd) as a key and established structure of FIP, including by making the FIPEd Chair an official Bureau member.
GLOBAL CONFERENCE ON PHARMACY & PHARMACEUTICAL SCIENCES EDUCATION

An exceptional event took place in November 2016: the Global Conference on Pharmacy and Pharmaceutical Sciences Education. This gathered pharmacy and pharmaceutical sciences leaders from across the globe in Nanjing, China, to set the future milestones for education and workforce development of pharmacists and pharmaceutical scientists, creating a global vision for transformative pharmacy and pharmaceutical sciences education.

The conference provided a platform for dialogue and established consensus among policymakers, education leaders and regulators on how pharmaceutical workforce competence can be assured through education. Six hundred participants from 47 countries and territories were represented. As a result, the global conference adopted:

- A global vision for the workforce and workforce development (in the context of education and training)
- A set of 13 pharmaceutical workforce development goals
- A set of 67 statements on pharmacy and pharmaceutical sciences education

The purpose of these documents is to advance education and foster full acceptance of responsibility and accountability for improving global health.

Dr Jim Campbell, director of the health workforce department, World Health Organization

“This is a remarkable achievement and I applaud FIP for its efforts in developing these Pharmaceutical Workforce Development Goals. The clear alignment with the World Health Organization’s human resource for health policies is welcome and demonstrates strong leadership for this critical health workforce.”

Dr Zhixiang Shi, associate professor, Chinese Pharmaceutical University

“With this conference, we are getting closer and closer to reaching international consensus on the way forward for pharmacy education.”

Rear Admiral Dr Pamela Schweitzer, chief pharmacy officer, U.S. Public Health Service

“Meeting the leaders of the world in the field of pharmacy was the highlight of this Conference. This is the start of a global movement for pharmacy.”

The conference was co-organised with the Chinese Pharmaceutical Association and supported by the American Association of Colleges of Pharmacy, China Pharmaceutical University and members of the FIP Corporate Roundtable on Education (AbbVie, Bayer, the Federation of Pharmaceutical Manufacturers’ Associations of Japan, GlaxoSmithKline, McCann Health, the Nagai Foundation and Pfizer).
FIP MEMBER ORGANISATION PROGRAMMES AND ACTIVITIES
(Exclusively available to FIP member organisations)

RESPONDING TO DISASTERS: GUIDELINES FOR PHARMACY

FIP-WHO TECHNICAL GUIDELINES: POINTS TO CONSIDER IN THE PROVISION BY HEALTH CARE PROFESSIONALS OF CHILDREN-SPECIFIC PREPARATIONS THAT ARE NOT AVAILABLE AS AUTHORISED PRODUCTS

AN OVERVIEW OF CURRENT PHARMACY IMPACT ON IMMUNISATION

TRANSFORMING OUR WORKFORCE

FIP STATEMENT ON "ENVIRONMENTALLY SUSTAINABLE PHARMACY PRACTICES: GREEN PHARMACY"

GLOBAL VISION FOR THE WORKFORCE AND WORKFORCE DEVELOPMENT

PHARMACEUTICAL WORKFORCE DEVELOPMENT GOALS

POLICY BRIEFING ON THE OWNERSHIP OF COMMUNITY PHARMACIES
(Exclusively available to FIP member organisations)

THREE ISSUES OF THE INTERNATIONAL PHARMACY JOURNAL
(March, July & November)

36 PAPERS IN THE PHARMACY EDUCATION JOURNAL

BIOWAIVER RIBAVIRIN MONOGRAPH

WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES VIDEO SERIES
(10 INTERVIEWS) AND ABSTRACTS

† Halim Basari, Brigadier General, Malaysia, on halal medicines

GLOBAL CONFERENCE ON PHARMACY & PHARMACEUTICAL SCIENCES EDUCATION VIDEO SERIES (SEVEN INTERVIEWS) AND ABSTRACTS

† Lucinda Maine, executive vice president and CEO, American Association of Colleges of Pharmacy, on the importance of leadership development
FIP strategic plan and statements
Work on a new strategic plan is under way, with a consultation being organised. The aim is to collectively prepare the future of FIP by setting up strategic objectives and renewed missions. We are also preparing four new FIP statements for consideration by the FIP Council on antimicrobial resistance, medicines information, emergency guidelines and self-care.

Non-communicable diseases
We have been collecting evidence on the roles of pharmacists in non-communicable diseases and the impacts of their interventions, and on how new technologies are supporting these new roles.

Women and the responsible use of medicines
Gathering evidence of the roles women play in contributing to good health and disease prevention, and of the roles of pharmacists in empowering women by providing them with the information they need to ensure the responsible use of medicines.

Harm reduction
Gathering evidence on the roles of pharmacists in policies, programmes and practices that aim to reduce the harms associated with the use of psychoactive drugs in people unable or unwilling to stop using them. The defining features are a focus on the prevention of harm, rather than on the prevention of drug use itself, and a focus on people who continue to use drugs.

Medicines information
We worked on setting out a vision for collaboration and action towards ensuring high quality medicines information around the world, through the use of strategies, with a report for publication in 2017.

A vision for pharmacy practice
All FIP sections contributed to a new strategic plan for the Board of Pharmaceutical Practice, intended to identify opportunities to improve the quality of pharmacy practice in every setting. This is due to be published in 2017.

Supply chain
FIP’s Board of Pharmaceutical Practice set up a working group with the objectives to provide an overview of the value that pharmacists add to the pharmaceutical supply chain. A report, due to be published in 2017, will aim to provide a global picture, taking the scarcity of pharmacists in many settings into consideration, and clearly identifying where the competencies of pharmacists are best used and most needed.
Future congresses

Work is under way for our annual congresses in Seoul, Republic of Korea (10–14 September 2017; “Medicines and beyond! The soul of pharmacy”), and Glasgow, UK (2–6 September 2018; “Pharmacy: Transforming outcomes!”) as well as our fifth pharmaceutical sciences congress in Stockholm, Sweden (21–24 May 2017; “Future medicines for one world — Systems approaches to drug discovery, development and clinical usage”). We look forward to discussing global pharmacy and pharmaceutical sciences with you in these exciting locations.

World Health Organization documents

In 2016, we reviewed and provided input into 17 draft WHO documents, including the WHO Global Model Regulatory Framework for medical devices such as in vitro diagnostics. Our contribution to these yet-to-be-published documents will continue.

Global pharmacy observatory

We worked on a new online pharmacy-related information hub that can be used by member organisations to inform advocacy work, policy development, decision-making, workforce intelligence and the advancement of pharmaceutical practice, sciences and education. The observatory should be launched at the end of 2017.

Leadership

FIP’s Young Pharmacists Group started working on a professional development resource “Leading with emotional intelligence” to be published in Spring 2017.

Support workforce

A report on the pharmacy support workforce, which describes the ways in which pharmacy technicians support pharmacists, will be released in 2017.

mHealth

A number of volunteers from FIP’s Young Pharmacists Group added to FIP’s knowledge on mobile-health tools that support pharmacists’ contributions to health promotion, health improvement and well-being of patients, with the aim of producing an overview of the different tools pharmacists are using in their practice for publication in late 2017.

Global trends

We worked on preparing an updated report on global trends in pharmacy, to be published in 2017.

Education and workforce

A report on the 2016 Global Conference on Pharmacy & Pharmaceutical Sciences Education (see p26) will act as a tool to facilitate the implementation of the vision and Statements on Pharmacy & Pharmaceutical Sciences Education (“Nanjing Statements”) around the world. FIP Education is also conducting work to outline the current state of global research and evaluation strategies in pharmaceutical education and workforce development, with a global report intended to guide member organisations in developing local and national research, development and evaluation strategies to be launched at the 2017 FIP congress in Seoul, Republic of Korea.

Global pharmacy observatory

We worked on a new online pharmacy-related information hub that can be used by member organisations to inform advocacy work, policy development, decision-making, workforce intelligence and the advancement of pharmaceutical practice, sciences and education. The observatory should be launched at the end of 2017.

Leadership

FIP’s Young Pharmacists Group started working on a professional development resource “Leading with emotional intelligence” to be published in Spring 2017.

Support workforce

A report on the pharmacy support workforce, which describes the ways in which pharmacy technicians support pharmacists, will be released in 2017.

mHealth

A number of volunteers from FIP’s Young Pharmacists Group added to FIP’s knowledge on mobile-health tools that support pharmacists’ contributions to health promotion, health improvement and well-being of patients, with the aim of producing an overview of the different tools pharmacists are using in their practice for publication in late 2017.

Global trends

We worked on preparing an updated report on global trends in pharmacy, to be published in 2017.
**FINANCES**

**BALANCE SHEET AT 31 DECEMBER 2016**

After appropriation of the results for 2016

Expressed in EURO

<table>
<thead>
<tr>
<th></th>
<th>31 DECEMBER 2016</th>
<th>31 DECEMBER 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FIXED ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>591 373</td>
<td>615 786</td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debtors, prepayments and accrued income</td>
<td>521 951</td>
<td>408 092</td>
</tr>
<tr>
<td>Cash at bank and in hand</td>
<td>2 173 931</td>
<td>2 442 053</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td>2 695 882</td>
<td>2 850 145</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>3 287 255</td>
<td>3 465 931</td>
</tr>
<tr>
<td><strong>CAPITAL AND RESERVES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital FIP</td>
<td>1 286 463</td>
<td>1 612 139</td>
</tr>
<tr>
<td>Capital FIP sections</td>
<td>540 184</td>
<td>544 006</td>
</tr>
<tr>
<td>Congress reserve</td>
<td>650 000</td>
<td>650 000</td>
</tr>
<tr>
<td>Board of Pharmaceutical Practice reserve</td>
<td>97 635</td>
<td>76 854</td>
</tr>
<tr>
<td>Board of Pharmaceutical Sciences reserve</td>
<td>131 442</td>
<td>147 051</td>
</tr>
<tr>
<td>Reserve HIV/AIDS</td>
<td>5 000</td>
<td>10 000</td>
</tr>
<tr>
<td>Reserve FIPed</td>
<td>131 751</td>
<td>65 460</td>
</tr>
<tr>
<td><strong>TOTAL CAPITAL AND RESERVES</strong></td>
<td>2 842 476</td>
<td>3 105 510</td>
</tr>
<tr>
<td><strong>PROVISIONS</strong></td>
<td>26 291</td>
<td>22 160</td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td>418 488</td>
<td>338 261</td>
</tr>
<tr>
<td><strong>TOTAL CAPITAL AND RESERVES AND LIABILITIES</strong></td>
<td>3 287 255</td>
<td>3 465 931</td>
</tr>
</tbody>
</table>
### INCOME

<table>
<thead>
<tr>
<th>Description</th>
<th>ACTUALS 2016</th>
<th>BUDGET 2016</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership fees</td>
<td>1 130 397</td>
<td>980 000</td>
<td></td>
<td>1 095 858</td>
</tr>
<tr>
<td>Congress revenues</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- FIP annual congress</td>
<td>1 032 007</td>
<td>1 000 000</td>
<td></td>
<td>1 691 974</td>
</tr>
<tr>
<td>Publications</td>
<td>522</td>
<td>5 000</td>
<td></td>
<td>174</td>
</tr>
<tr>
<td>Other income BPS</td>
<td>1 048</td>
<td>-</td>
<td></td>
<td>2 464</td>
</tr>
<tr>
<td>Section income</td>
<td>69 250</td>
<td>100 000</td>
<td></td>
<td>98 241</td>
</tr>
<tr>
<td>FIPEd income</td>
<td>199 213</td>
<td>180 000</td>
<td></td>
<td>176 947</td>
</tr>
<tr>
<td>WHPA Counterfeit Campaign income</td>
<td>31 802</td>
<td>-</td>
<td></td>
<td>53 035</td>
</tr>
<tr>
<td>Other income</td>
<td>7 628</td>
<td>50 000</td>
<td></td>
<td>52 948</td>
</tr>
</tbody>
</table>

**TOTAL INCOME** 2 471 867  2 315 000  156 867  3 171 641

### EXPENSES

<table>
<thead>
<tr>
<th>Description</th>
<th>ACTUALS 2016</th>
<th>BUDGET 2016</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership costs</td>
<td>131 831</td>
<td>-</td>
<td></td>
<td>100 834</td>
</tr>
<tr>
<td>Personnel costs</td>
<td>924 125</td>
<td>900 000</td>
<td></td>
<td>908 881</td>
</tr>
<tr>
<td>Office costs</td>
<td>161 479</td>
<td>150 000</td>
<td></td>
<td>117 868</td>
</tr>
<tr>
<td>Executive committee and bureau meeting costs</td>
<td>66 293</td>
<td>136 000</td>
<td></td>
<td>68 950</td>
</tr>
<tr>
<td>Travel expenses external representation</td>
<td>49 463</td>
<td>50 000</td>
<td></td>
<td>43 562</td>
</tr>
<tr>
<td>Website and IT</td>
<td>66 178</td>
<td>70 000</td>
<td></td>
<td>117 426</td>
</tr>
<tr>
<td>Depreciation of fixed assets</td>
<td>27 735</td>
<td>25 000</td>
<td></td>
<td>26 956</td>
</tr>
<tr>
<td>Remuneration project</td>
<td>-</td>
<td>-</td>
<td></td>
<td>41 857</td>
</tr>
<tr>
<td>Medicine shortage project</td>
<td>-</td>
<td>-</td>
<td></td>
<td>40 000</td>
</tr>
<tr>
<td>Other (special) projects</td>
<td>18 075</td>
<td>5 000</td>
<td></td>
<td>13 627</td>
</tr>
<tr>
<td>FIP congress costs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- FIP annual congress</td>
<td>828 708</td>
<td>800 000</td>
<td></td>
<td>1 041 643</td>
</tr>
<tr>
<td>Publications</td>
<td>40 694</td>
<td>45 000</td>
<td></td>
<td>46 860</td>
</tr>
<tr>
<td>Subventions</td>
<td>23 707</td>
<td>32 000</td>
<td></td>
<td>18 242</td>
</tr>
<tr>
<td>Expenses BPS</td>
<td>78 219</td>
<td>99 000</td>
<td></td>
<td>77 766</td>
</tr>
<tr>
<td>Expenses BPS</td>
<td>54 657</td>
<td>63 000</td>
<td></td>
<td>47 404</td>
</tr>
<tr>
<td>Sections’ operating costs</td>
<td>73 072</td>
<td>100 000</td>
<td></td>
<td>66 915</td>
</tr>
<tr>
<td>FIPEd expenses</td>
<td>132 922</td>
<td>180 000</td>
<td></td>
<td>136 123</td>
</tr>
<tr>
<td>Building Maintenance Fund</td>
<td>15 000</td>
<td>15 000</td>
<td></td>
<td>15 000</td>
</tr>
<tr>
<td>WHPA Counterfeit Campaign</td>
<td>31 802</td>
<td>-</td>
<td></td>
<td>53 035</td>
</tr>
<tr>
<td>Business development</td>
<td>8 459</td>
<td>20 000</td>
<td></td>
<td>14 459</td>
</tr>
</tbody>
</table>

**TOTAL EXPENSES** 2 732 418  2 690 000  42 418  2 997 407

<table>
<thead>
<tr>
<th>Description</th>
<th>ACTUALS 2016</th>
<th>BUDGET 2016</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating result</td>
<td>(260 552)</td>
<td>(375 000)</td>
<td></td>
<td>114 448</td>
</tr>
<tr>
<td>Financial result</td>
<td>(2 483)</td>
<td>30 000</td>
<td></td>
<td>9 327</td>
</tr>
</tbody>
</table>

**NET RESULT BEFORE APPROPRIATION** (263 035)  (345 000)  81 965  183 561

### Appropriation of the results

<table>
<thead>
<tr>
<th>Description</th>
<th>ACTUALS 2015</th>
<th>ACTUALS 2016</th>
<th>BUDGET 2016</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPP general reserves</td>
<td></td>
<td>20 781</td>
<td>8 000</td>
<td></td>
<td>12 234</td>
</tr>
<tr>
<td>BPS general reserves</td>
<td>(15 609)</td>
<td>(22 000)</td>
<td></td>
<td></td>
<td>6 940</td>
</tr>
<tr>
<td>Section capital</td>
<td>(3 822)</td>
<td>-</td>
<td></td>
<td></td>
<td>31 326</td>
</tr>
<tr>
<td>Regional forums reserve</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td>(4 859)</td>
</tr>
<tr>
<td>Reserve FIPed</td>
<td>66 291</td>
<td>-</td>
<td></td>
<td></td>
<td>40 825</td>
</tr>
<tr>
<td>Reserve HIV/AIDS</td>
<td>(5 000)</td>
<td>-</td>
<td></td>
<td></td>
<td>5 975</td>
</tr>
<tr>
<td>FIP capital</td>
<td>(325 676)</td>
<td>(331 000)</td>
<td></td>
<td></td>
<td>110 975</td>
</tr>
</tbody>
</table>

**TOTAL APPROPRIATION** (263 035)  (345 000)  81 965  183 561